Neil F. McFarlane
Tracked across 2 events · 35 articles · First seen Jun 08, 2026 · Last active Aug 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Neil F. McFarlane, Zevra's CEO, is implicated in the investigation due to his 2024 earnings call statement about arimoclomol's approval prospects. His statements are under scrutiny for potential misleading claims.
Jul 24, 2026 · 29 articles
Regulatory
Impact: Neil F. McFarlane, as President and CEO of Zevra Therapeutics, expressed satisfaction with the strengthened intellectual property protection for MIPLYFFA.
Jun 08, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Neil F. McFarlane live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard